LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Conditions
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Trial Timeline
Feb 4, 2015 → Sep 29, 2022
NCT ID
NCT02333370About LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin
LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin is a phase 1 stage product being developed by Novartis for Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02333370. Target conditions include Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02333370 | Phase 1 | Completed |
Competing Products
20 competing products in Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer